ArcticZymes Technologies appoints a Chief Scientific Officer (CSO)

01 Dec 2022 14:32 CET

Tromsø, Norway, 1[st] December 2022 - ArcticZymes Technologies ASA (OSE: AZT)
announces the appointment of Dr. Darren Ellis as its first Chief Scientific
Officer (CSO).

ArcticZymes Technologies has today appointed Dr. Darren Ellis as its first Chief
Scientific Officer.  Dr. Ellis brings over 20 years of industrial R&D experience
(from Solexa (now Illumina) and ThermoFisher Scientific) in leading and
developing molecular research and In Vitro Diagnostic (IVD) applications,
technologies and products.  Furthermore, he has global expertise in Business-to
-Business (B2B) application development, successfully helping commercial
partners and customers to bring their technologies and product developments to
market.

Dr. Ellis joined the Company in March this year to lead the establishment of the
Application Laboratory at Oslo Science Park and to recruit an experienced team
of application scientists. The laboratory is operational and currently focussing
on the development of workflow applications related to infectious disease
testing.

As CSO, Dr. Ellis will support the Company to strategically expand and optimise
the Company´s innovation capabilities and efforts in Norway and internationally
as the Company grows both organically and inorganically. He will lead an
international and experienced scientific team with the ability to bring further
cutting edge and high-value innovations to market, hence, elevating the
innovation pipeline to the next level.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"ArcticZymes is delighted to welcome Dr. Ellis as CSO. I had the pleasure to
work directly with Darren earlier in my career in supporting commercial partners
to market with world leading technologies."

Dr. Darren Ellis, ArcticZymes Technologies, CSO, said:

"I am pleased to be joining ArcticZymes as CSO at this exciting phase of the
Company´s growth journey and to lead future technology development. The Company
has a strong product portfolio, an innovative pipeline and a great reputation
with our customers. I am looking forward to working with a highly accomplished
and international team to achieve our mission to become Europe's leading
independent enzyme manufacturer."

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter Tel: +47 46 85 91 46
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.

More information:
Access the news on Oslo Bors NewsWeb site

577230_AZT_Appointment_of_CSO_01122022.pdf